A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

NCT03475953 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

747

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Not MSI-H or MMR-deficient
GIST
Oesophageal or Gastric Carcinoma
Biliary Tract Cancer
Hepatocellular Carcinoma
Soft-tissue Sarcoma
Thyroid Cancer
Gastro-enteropancreatic Neuroendocrine Tumor
Non-small Cell Lung Cancer
Solid Tumor, Adult
Urothelial Carcinoma
HPV-Related Carcinoma
Triple Negative Breast Cancer
Renal Carcinoma
Mesotheliomas Pleural

Interventions

DRUG: Phase 1 : Regorafenib
DRUG: Phase 1 : Avelumab
DRUG: Phase 2 : Regorafenib
DRUG: Phase 2 : Avelumab
DRUG: Phase 2: low-dose Regorafenib

Sponsor

Institut Bergonié

Collaborators

[object Object]
[object Object]